Literature DB >> 30675417

Current and future treatment options for managing hyperkalemia.

Matthew R Weir1.   

Abstract

Hyperkalemia is associated with life-threatening cardiac arrhythmias and increased mortality. Hyperkalemia is most often observed in patients with chronic kidney disease and/or in those with congestive heart failure being treated with drugs that limit renal potassium excretion, especially drugs that inhibit the renin-angiotensin-aldosterone system. Treatment of hyperkalemia may be either acute, as needed during rapid changes in serum potassium, which are associated with cardiac arrhythmia, or chronic, which stabilizes serum potassium levels and limits the development of life-threatening arrhythmias. There are a number of both acute and chronic treatments available for the treatment of hyperkalemia, but some are limited by complex administration requirements and/or serious side effects. Hyperkalemia remains a vexing problem for clinicians, particularly in the care of patients with chronic kidney disease and cardiovascular disease.

Entities:  

Keywords:  RAAS inhibitors; ZS-9; chronic kidney disease; congestive heart failure; hyperkalemia; patiromer

Year:  2016        PMID: 30675417      PMCID: PMC6340903          DOI: 10.1016/j.kisu.2016.01.005

Source DB:  PubMed          Journal:  Kidney Int Suppl (2011)        ISSN: 2157-1716


  2 in total

1.  Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology.

Authors:  Stefano Bianchi; Filippo Aucella; Luca De Nicola; Simonetta Genovesi; Ernesto Paoletti; Giuseppe Regolisti
Journal:  J Nephrol       Date:  2019-05-22       Impact factor: 3.902

2.  Cecum perforation associated with a calcium polystyrene sulfonate bezoar - a rare entity.

Authors:  David Carvalho Fiel; Iolanda Santos; Joana Eugénio Santos; Rita Vicente; Susana Ribeiro; Artur Silva; Beatriz Malvar; Carlos Pires
Journal:  J Bras Nefrol       Date:  2018-12-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.